Skip to main content
Publications
Marsal JR, Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights. Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
Rubio-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J, Spanish Group for Research on Sarcoma. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol. 2015 Sep;22(9):2948-57. doi: 10.1245/s10434-014-4360-8
Martinez-Fernandez A, Garcia-Albeniz X, Pineda E, Visa L, Gallego R, Codony-Servat J, Auge JM, Longaron R, Gascon P, Lacy A, Castells A, Maurel J. Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann Surg Oncol. 2009 May;16(5):1412-20. doi: 10.1245/s10434-009-0405-9